Alvotech Shares Rise After FDA Accepts Entyvio Biosimilar Application for Review
Alvotech's shares increased by 12% in premarket trading after the U.S. Food and Drug Administration accepted its Biologics License Application for AVT16, an interchangeable biosimilar to Takeda’s Entyvio. The FDA acceptance marks a key regulatory milestone that could lead to commercialization of AVT16 in the United States.
Topics: alvotech biosimilars entyvio fda